Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Owings Mill, Maryland Clinical Trials

A listing of Owings Mill, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (5) clinical trials

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Primary Objective of the Master Protocol (LUNGMAP) The primary objective of this screening study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol. Secondary Objectives Screening Success Rate Objective To evaluate the screen success rate defined as ...

Phase

3.28 miles

Learn More »

Laboratory Smoking of Marijuana "Blunts"

This is a double-blind within-subjects clinical laboratory study comparing the product appeal and abuse liability-related subjective effects of different flavored cigar wrappers for marijuana blunts.

Phase

6.55 miles

Learn More »

Irinotecan Hydrochloride Temozolomide and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

PRIMARY OBJECTIVES: I. To determine whether administration of eflornithine (DFMO) in combination with dinutuximab, irinotecan hydrochloride (irinotecan) and temozolomide results in an improved response rate compared to dinutuximab, irinotecan and temozolomide in patients with relapsed or refractory neuroblastoma and therefore is a therapeutic regimen worthy of further testing in patients ...

Phase

7.47 miles

Learn More »

A Clinical Investigation to Evaluate Effectiveness and Safety of Princess FILLER Lidocaine in Correction of NLF

to assess the effectiveness of Princess Filler Lidocaine in reducing the severity of nasolabial folds compared to Juvederm Ultra XC, based on the independent blinded evaluating investigator live assessment using the Nasolabial Folds Severity Rating Scale (NLF-SRS) at Week 24 after initial treatment and relative to Baseline assessments

Phase N/A

7.81 miles

Learn More »

the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

This study is an open-label, randomized, expanded/phase II study in subjects with metastatic castrate resistant prostate cancer (mCRPC) who progressed after either abiraterone or enzalutamide. All subjects will be randomized to take 400 mg or 500 mg of GT0918 by oral administration once daily on an empty stomach (2-3 hours ...

Phase

9.46 miles

Learn More »